HABS-HD - Core C - Clinical Core

HABS-HD - 核心 C - 临床核心

• 批准号: 10493847
• 负责人: Sid E O'Bryant
• 金额: $ 1134.45万
• 依托单位: UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493847
• 关键词: Adherence; Adult; African American population; Age; Alzheimer' s Disease; Alzheimer' s disease related dementia; Ancillary Study; Back; Behavioral; Biological Markers; Blood specimen; Brain; Cataloging; Cerebrospinal Fluid; Clinical; Clinical Data; Cognitive; Collaborations; Collection; Communities; Community Relations; Consensus; Consent; Data; Data Collection; Diagnosis; Educational Materials; Enrollment; Ensure; Ethnic group; Family; Family health status; Feedback; Focus Groups; Foundations; Goals; Health; Health Disparities Research; Health Personnel; Image; Informatics; Informed Consent; Infrastructure; Interview; Letters; Magnetic Resonance Imaging; Measures; Medical; Mexican Americans; Modeling; Monitor; Neuropsychology; Not Hispanic or Latino; Parents; Participant; Persons; Population; Positron-Emission Tomography; Prevention strategy; Procedures; Process; Protocols documentation; Real-Time Systems; Research; Sampling; Spinal Puncture; Standardization; Time; Update; Visit; Work; aging brain; base; biobank; care providers; clinical diagnosis; cohort; electronic data capture system; future implementation; health disparity; health goals; informant; neuroimaging; novel; outreach; precision medicine; programs; racial and ethnic; recruit; social culture; treatment strategy; virtual; web site

HABS-HD CLINICAL CORE (CORE C) ABSTRACT The long-term goal of the Health & Aging Brain Study – Health Disparities (HABS-HD) is to establish a population-specific informed precision medicine for novel treatment and prevention strategies for Alzheimer’s disease (AD) as called for in NIA AD+ADRD Milestone 1. The Clinical Core (Core C) will meet this goal by continuing to conduct all direct participant interviews, assessments, imaging, and other protocol components (parent study and/or ancillary studies). By the time of the initiation of the U19, the cohort will consist of 3,000 community-dwelling participants ages 50 and above (n=1,000 African Americans [AA], 1,000 Mexican Americans [MA], and 1,000 non-Hispanic whites [NHW]). Visit one (V1) and 24-month longitudinal V2 data will be available at initiation of the U19 among the MA and NHW participants with V1 data available for the AA participants. As part of this U19, we will continue 24-month assessments of the existing cohort as well as enroll an additional 1,500 participants (n=500 per racial/ethnic group; age 30-49) for a more comprehensive examination of AT(N) defined biomarkers across adulthood among the three largest racial/ethnic groups in the U.S. Core C is responsible for reviewing all data for assignment of research diagnoses (medical and cognitive) as well as providing feedback to participants, families and health care providers as part of our “give back” to the community as indicated during the informed consent process by the participant. The data collected by Core C will be crucial for all Projects and will also be made available to the scientific community via LONI. The Clinical Core Aims are as follows: Aim 1 (Data Capture): In collaboration with all Cores, continue to follow harmonized protocols for the collection, processing, cataloging, storage and distribution of demographic, clinical and imaging data in support of overall program goals. Aim 2 (CSF Substudy): Conduct cerebrospinal fluid (CSF) collection substudy. Aim 3 (Consensus Reviews and Feedback): Continue to conduct consensus reviews to ensure appropriate assignment of research-based clinical diagnoses (cognitive and medical) and provide feedback to participants, families and heath care providers as indicated during informed consent process. Aim 4 (Collaboration): Collaborate with Cores and Projects. Aim 5 (Brain Bank): Build foundation, community relations and infrastructure for future implementation of HABS-HD Brain Bank. Aim 6 (Cross-Study Comparisons): Work collaboratively with other AD+ADRD projects and programs for cross-study comparisons leveraging HABS-HD clinical data. In collaboration with the Administrative Core (Core A), work to ensure cross-study comparisons with ongoing initiatives such as ADNI, WHICAP, SOL/INCA, LEADS, ABC-DS, New IDEAS, ADCs and others.

HABS-HD临床核心（核心C）摘要 健康与老龄化大脑研究-健康差异（HABS-HD）的长期目标是建立一个 针对特定人群的精确医疗，用于阿尔茨海默病的新治疗和预防策略 NIA AD+ADRD里程碑1中要求的AD。临床核心（核心C）将通过以下方式实现这一目标： 继续进行所有直接参与者访谈、评估、成像和其他方案组成部分 （母研究和/或辅助研究）。到19岁以下儿童开始时，该队列将由3，000人组成 年龄在50岁及以上的社区居住参与者（n= 1，000名非裔美国人[AA]，1，000名墨西哥人[AA]） 美国人[MA]和1,000名非西班牙裔白人[NHW]）。访视1（V1）和24个月纵向V2数据将 在MA和NHW参与者中启动U19时可用，AA可获得V1数据 参与者作为U19的一部分，我们将继续对现有队列进行24个月的评估， 另外1，500名参与者（每个种族/民族组n=500;年龄30-49），以进行更全面的 研究中三个最大的种族/民族群体中，在成年期检查AT（N）定义的生物标志物。 美国核心C负责审查所有数据，以分配研究诊断（医学和认知） 以及向参与者、家庭和医疗保健提供者提供反馈，作为我们“回馈”的一部分， 参与者在知情同意过程中指出的社区。Core收集的数据 C对所有项目都至关重要，也将通过LONI提供给科学界。的 临床核心目标如下：目标1（数据采集）：与所有核心合作，继续遵循 人口统计数据的收集、处理、编目、储存和分发的统一协议， 临床和影像学数据，以支持总体计划目标。目标2（CSF子研究）：进行脑脊液 液体（CSF）采集子研究。目标3（共识审查和反馈）：继续进行共识 审查，以确保适当分配基于研究的临床诊断（认知和医学）， 根据知情同意过程中的指示，向参与者、家属和医疗保健提供者提供反馈 过程目标4（协作）：与核心和项目协作。目标5（人才库）：建立基础， 社区关系和基础设施，以供今后实施人居署-高血压脑库。目标6（交叉研究 比较）：与其他AD+ADRD项目和计划合作进行交叉研究比较 利用HABS-HD临床数据。与行政核心（核心A）合作，努力确保 与ADNI、WHICAP、SOL/印加CA、LEADS、ABC-DS、New IDEAS、ADC和其他。